Rapid Micro Biosystems (RPID) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Business overview and recent progress

• Focuses on automating microbial quality control in pharmaceutical manufacturing, replacing outdated manual methods with the Growth Direct platform.

• Achieved a milestone of 150 global placements, with most customers among the top 20 global pharma companies.

• Reported record revenue and over 30% revenue growth in the past quarter.

• Growth Direct platform offers automation, improved data integrity, and faster results compared to legacy methods.

• Customers benefit from faster market release, quicker issue detection, and increased inventory turnover.

Adoption drivers and customer journey

• Adoption is driven by the need for workflow standardization, data integrity, and speed.

• Large customers often deploy multiple systems across sites or regions, with initial placements followed by broader rollouts.

• Sales cycles for new customers average 9–12 months, with follow-on orders moving faster.

• High-volume customers typically dedicate systems to specific applications, while smaller customers may use multi-application systems.

Market environment and pricing

• Operates mainly in commercial pharma and biotech, largely insulated from early-stage biotech funding headwinds.

• Faces increased budget scrutiny, but strategic projects and strong ROI help secure funding.

• Pricing discussions are common, with volume-based discounts offered; ROI is a key factor in purchase decisions.